Cargando…
The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design
RATIONALE: In patients with acute cerebral ischemia, the rate of stroke, myocardial infarction, or death during 90 days was reported to be non-significantly lower with ticagrelor compared with aspirin, with no increase in major hemorrhage. Dual antiplatelet therapy may be more effective in this sett...
Autores principales: | Johnston, S Claiborne, Amarenco, Pierre, Denison, Hans, Evans, Scott R, Himmelmann, Anders, James, Stefan, Knutsson, Mikael, Ladenvall, Per, Molina, Carlos A, Wang, Yongjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826854/ https://www.ncbi.nlm.nih.gov/pubmed/30747613 http://dx.doi.org/10.1177/1747493019830307 |
Ejemplares similares
-
Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial
por: Tank, Amarjeet, et al.
Publicado: (2023) -
Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin
por: Amarenco, Pierre, et al.
Publicado: (2020) -
Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial
por: Amarenco, Pierre, et al.
Publicado: (2020) -
Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack
por: Wang, Yongjun, et al.
Publicado: (2022) -
Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial
por: Wang, Yongjun, et al.
Publicado: (2021)